Form 4: Catalyst Pharmaceuticals Executive Sells Shares After Option Exercise

Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, sold shares on August 9, 2024, following the exercise of stock options.

Summary

• On August 9, 2024, Jeffrey Del Carmen, the Chief Commercial Officer of Catalyst Pharmaceuticals, executed multiple transactions involving the company's common stock.
• Del Carmen sold 6,058 shares at $18.44 per share and another 30,000 shares at a weighted average price of $18.42 per share.
• These sales were conducted on the open market for personal reasons.
• Concurrently, Del Carmen exercised options to purchase 30,000 shares at $2.86 per share.
• Following these transactions, Del Carmen directly owns 12,369 shares of common stock and holds options for 804,019 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports standard insider trading activity. The sales are stated to be for personal reasons, mitigating potential negative interpretations.

Management Comments

• Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but the stated reason for personal financial management mitigates concerns.

Key Dates